Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. (Nasdaq: RLAY) is a clinical-stage biotechnology company pioneering drug discovery through its Dynamo™ platform, which analyzes protein motion to develop precision therapies for oncology and genetic diseases. This page provides real-time access to official company announcements, research breakthroughs, and strategic developments.
Investors and industry professionals will find curated updates including clinical trial progress, regulatory milestones, and partnership announcements. All content is sourced directly from Relay Therapeutics’ communications and verified financial disclosures, ensuring reliability for decision-making.
Key coverage areas include innovations in small molecule therapeutics, updates on the Dynamo platform’s applications, and analyses of Relay’s position within the precision medicine landscape. Content is organized chronologically for easy tracking of the company’s evolution.
Bookmark this page to monitor Relay Therapeutics’ advancements in targeting historically undruggable proteins. For comprehensive insights into RLAY’s scientific and corporate developments, revisit regularly or subscribe to Stock Titan’s update alerts.
Relay Therapeutics (Nasdaq: RLAY) announced plans to report its second quarter 2021 financial results on August 12, 2021, after market closure. The company will not hold a teleconference to discuss these results. Relay Therapeutics is a clinical-stage precision medicine firm focused on transforming drug discovery using its innovative Dynamo™ platform, targeting oncology and genetic diseases. The company aims to tackle challenging protein targets through an integration of computational and experimental technologies.
Relay Therapeutics (Nasdaq: RLAY) will participate in two upcoming fireside chats: at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 3:50 pm ET, and at the JMP Securities Life Science Conference on June 17, 2021, at 10:30 am ET. These discussions will be webcast live and accessible via the Investor page of Relay's website. Archived replays will be available for 90 days post-event. Relay Therapeutics, a clinical-stage precision medicine company, aims to enhance drug discovery using its Dynamo™ platform focused on oncology and genetic diseases.
Relay Therapeutics (Nasdaq: RLAY) will participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit on May 20, 2021, at 11:20 AM ET. The event will be webcast live and accessible via the Investor page of Relay's website. A replay of the chat will be available for 90 days post-event, until August 18, 2021. Relay Therapeutics focuses on precision medicine, using its Dynamo™ platform to enhance drug discovery for challenging protein targets, particularly in oncology and genetic diseases.
Relay Therapeutics reported its first quarter 2021 financial results, highlighting a cash reserve of approximately $726.1 million, up from $678.1 million at the end of 2020, ensuring funding into 2024. The company focuses on advancing its clinical programs, including RLY-1971 and RLY-4008, and has made its first acquisition of ZebiAI to enhance its Dynamo™ platform. However, the net loss widened to $42.2 million, compared to $24.9 million in Q1 2020, with increased R&D and G&A expenses.
Relay Therapeutics (Nasdaq: RLAY) has appointed Dr. Patrick Riley as the senior vice president of artificial intelligence, enhancing its computational strength in drug discovery. With 15 years of experience from Google, Dr. Riley will spearhead a computational team focused on applying AI to drug development. His expertise in machine learning and data science is expected to strengthen Relay's innovative approach, particularly following its recent acquisition of ZebiAI. The company aims to tackle challenging protein targets to deliver transformative therapies.
Relay Therapeutics (Nasdaq: RLAY) will participate in a fireside chat at the Bank of America 2021 Health Care Conference on May 11, 2021, at 8:45 a.m. ET. This event can be accessed live via Relay’s Investor page, with an archived replay available for 24 hours post-event, until August 13, 2021. Relay Therapeutics is a clinical-stage precision medicines company utilizing its innovative Dynamo™ platform to advance small molecule discoveries for targeted oncology and genetic diseases.
Relay Therapeutics announced the appointments of Tara O'Meara as Senior VP of Clinical Development Operations and Dr. Charles Ferté as VP, Global Medical Lead for RLY-4008. Both bring extensive experience in drug development, aimed at enhancing Relay's clinical capabilities. O'Meara has over a decade of experience in rare genetic diseases and oncology, while Dr. Ferté has 15 years in oncology R&D, including roles at AstraZeneca. This leadership expansion is expected to strengthen Relay's drug pipeline as they continue developing therapies for critical conditions.
Relay Therapeutics has announced its acquisition of ZebiAI for $85 million, comprising $20 million in cash and $65 million in stock. This acquisition aims to enhance Relay’s Dynamo™ platform, integrating ZebiAI's extensive experimental data and machine learning models to accelerate drug discovery. The deal allows for additional milestone payments up to $85 million and a 10% share of future collaboration revenues, capped at $100 million. Relay anticipates this acquisition will strengthen its position in the biotech sector and support its operational plans into 2024.
Relay Therapeutics reported strong advancements in 2020, including two programs, RLY-1971 and RLY-4008, entering clinical development. The company raised $460 million in its IPO and secured a collaboration with Genentech for RLY-1971, boosting its finances to approximately $678.1 million. Net income reached $35.3 million in Q4 2020, a significant improvement over the previous year’s loss. R&D expenses rose to $32.1 million in Q4 2020, reflecting increased clinical trial activity. Relay emphasized 2021 as a pivotal year for executing its drug discovery mission.
RLY-4008, a novel oral small molecule inhibitor of FGFR2 developed by Relay Therapeutics, shows promising preclinical results against FGFR2-altered cancers. The drug exhibits strong activity against known resistance mutations and demonstrates efficacy in both cellular and in vivo preclinical models. The data will be presented at the AACR Annual Meeting scheduled for April 10-15 and May 17-21, 2021. Initial clinical data for RLY-4008 is expected later in 2021. The company aims to advance treatment options for patients with advanced or metastatic solid tumors.
